American Psychiatric Association

In a presentation for the American Psychiatric Association, Elinore McCance-Katz says helpline calls have dramatically increased since the COVID-19 pandemic.

Substance use is common in as many as 10% of pregnant women in the US. What are the risks of each substances, and what are the proven methods of treatment?

How do comorbidities influence patients' life expectancies? What is the role of public health programs?

Why the field lacks behind in effective diagnostic tools, which could better inform tailored therapy.

The novel target therapy has reported promising early findings. What is its potential?

In a presentation at the APA Spring Highlights Meeting 2020, Patrice Harris, MD, says telemedicine is crucial to maintain care while decreasing the risk of COVID-19.

How have natural-cause mortality rates changed over time in an international population?

How psychiatry can catch up to other specialties in accurate, timely diagnostics based on molecular breakthrough.

It might be particularly difficult for psychiatrists to treat trauma patients through telehealth means.

SEP-363856 is showing initial efficacy and long-term safety in adult patients.

David Jiang, MD, explains some preffered therapies and medications for trauma patients.

Data regarding major adverse events remain unreliable due to a lack of a patient registry.

A public health expert shares insight on the positives and pitfalls learned from stigma-reduction campaigns.

A discussion on how difficulties accepting the drug addiction public health crisis is affecting the rate of care-seeking patients.

The data may be helpful for clinicians in developing treatment courses for patients exhibiting withdrawal symptoms from short-acting opioids.

David Walling, PhD, discussed the biggest misconceptions about patients with schizophrenia, including the high rate of suicide among this population.

Employed patients who were also impaired on functional capacity measures, showed larger overall treatment response than unemployed patients regardless of functional capacity measure scores.

David Walling, PhD, discussed the results from a pharmacokinetic and safety study that evaluated aripiprazole lauroxil NanoCrystal Dispersion therapy initiation.

The technology includes enhanced features like a patient management system that increases the ease of use for physicians.

The 14-point guideline included recommendations for initial psychiatric evaluation and assessment, treatment goals and plans, use of multiple medications, and for patients that are pregnant or breastfeeding.

MDD and PTSD are significantly associated with military trauma and PTSD specifically, is at an increased with military sexual trauma among females.

The use of the popular smartphone application Pokémon GO—and possibly similar games—could have potential therapeutic benefits for those with mental illness.

According to survey data released by the American Psychiatric Association, almost 50% of Americans believe the crisis is impacting their peers, and 31% know someone addicted to opioids.

If approved, therapy would be the first of its kind to target Glx for the treatment of bipolar depression.

The mean level of anxiety has increased 5 points since 2017 on a 100-point scale, with Baby Boomers reporting a 7-point jump over the last year.

Women who continued using antipsychotic medications during pregnancy had an absolute risk of 4.2% to 12% of developing gestational diabetes.

History of psychiatric disorder, especially in fathers and brothers, is highly valuable information to identify women most at risk for postpartum psychiatric illness.

Patients that had their medication selection guided by the GeneSight pharmacogenomic testing were 50% more likely to achieve remission and 30% more likely to achieve treatment response.

Patients with cannabis and cocaine use disorder have different impulsivity profiles, especially with relation to differences in attentional impulsiveness.

Results demonstrate potential to address a significant unmet for more than 30% of those suffering from treatment-resistant depression.